Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis - PubMed
4 hours ago
- #MASH
- #Liver Fibrosis
- #Tirzepatide
- Tirzepatide is studied for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) with liver fibrosis.
- The study was published in the New England Journal of Medicine (NEJM) with DOI: 10.1056/NEJMoa2401943.
- The clinical trial results were published on June 8, 2024, and the article appeared in the July 25, 2024 issue.
- An erratum was issued for the original article.